Beth Woods

2.4k citations

59 papers · 1.5k indexed · 1 hit paper · h-index 15

Impact in

Economics and Econometrics top 5%
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
Statistics, Probability and Uncertainty top 5%
- Meta-analysis and systematic reviews

Papers in ⓘ

Applied Microbiology and Biotechnology 8
- Antibiotic Use and Resistance 8
Statistics, Probability and Uncertainty 9
- Meta-analysis and systematic reviews 9

Co-authors: Mark Sculpher (19 shared papers)Karl Claxton (7 shared papers)Paul Revill (6 shared papers)Neil Hawkins (11 shared papers)David A. Scott (7 shared papers)E.G. Sideris (3 shared papers)Stephen Palmer (4 shared papers)Marta Soares (5 shared papers)
Journals: Value in Health (10 papers)PharmacoEconomics (4 papers)Health Technology Assessment (3 papers)BMJ Global Health (3 papers)BMC Medical Research Methodology (3 papers)
Partner nations: United Kingdom United States Switzerland

In The Last Decade

Beth Woods

51 papers receiving 1.5k citations

Hit Papers

align trajectories log scale

Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research 2016 · 574 citations

Peers

Countries citing papers authored by Beth Woods

Since Specialization

Citations

This map shows the geographic impact of Beth Woods's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth Woods with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth Woods more than expected).

Fields of papers citing papers by Beth Woods

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beth Woods. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth Woods. The network helps show where Beth Woods may publish in the future.

Co-authors

The 25 scholars most cited alongside Beth Woods, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Beth Woods Line = papers co-authored together Beth Woods links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 59 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research Value in Health ·Beth Woods, Paul Revill, Mark Sculpher, Karl Claxton Hit paper breakdown →	2016	574
2	Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorial BMC Medical Research Methodology ·Beth Woods, Neil Hawkins, David A. Scott	2010	230
3	Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now? Value in Health ·Beth Woods, E.G. Sideris, Stephen Palmer, Nicholas Latimer, Marta Soares	2020	88
4	Individual patient data network meta-analysis of mortality effects of implantable cardiac devices Heart ·Beth Woods, Neil Hawkins, Stuart Mealing, Alex J. Sutton, William T. Abraham, John F. Beshai, H. H. Klein, Mark Sculpher, Chris Plummer, Martín Cowie	2015	79
5	Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee PLoS ONE ·Beth Woods, Andrea Manca, Helen Weatherly, Pedro Saramago, E.G. Sideris, Christina Giannopoulou, Stephen Rice, Mark Corbett, Andrew J. Vickers, Matthew Bowes, Hugh MacPherson, Mark Sculpher	2017	56
6	Acupuncture for chronic pain and depression in primary care: a programme of research SHILAP Revista de lepidopterología ·Hugh MacPherson, Andrew J. Vickers, Martin Bland, David Torgerson, Mark Corbett, Eldon Spackman, Pedro Saramago, Beth Woods, Helen Weatherly, Mark Sculpher, Andrea Manca, Stewart Richmond, Ann Hopton, Janet Eldred, Ian Watt	2017	39
7	Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors Leukemia Research ·J. H. Lipton, Peter Bryden, M. Sidhu, Hui Huang, Lisa J. McGarry, Stephanie Lustgarten, Stuart Mealing, Beth Woods, Jo Whelan, Neil Hawkins	2014	38
8	No Study Left Behind: A Network Meta-Analysis in Non–Small-Cell Lung Cancer Demonstrating the Importance of Considering All Relevant Data Value in Health ·Neil Hawkins, David A. Scott, Beth Woods, Nicholas Thatcher	2009	35
9	How Far Do You Go? Efficient Searching for Indirect Evidence Medical Decision Making ·Neil Hawkins, David A. Scott, Beth Woods	2009	28
10	Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure Heart ·Stuart Mealing, Beth Woods, Neil Hawkins, Martín Cowie, Chris Plummer, William T. Abraham, John F. Beshai, Helmut Klein, Mark Sculpher	2016	26
11	‘Arm‐based’ parameterization for network meta‐analysis Research Synthesis Methods ·Neil Hawkins, David A. Scott, Beth Woods	2015	22
12	Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem? Value in Health ·Abigail Colson, Alec Morton, Christine Årdal, Kalipso Chalkidou, Sally C. Davies, Louis P. Garrison, Mark Jit, Ramanan Laxminarayan, Itamar Megiddo, Chantal Morel, Justice Nonvignon, Kevin Outterson, John Rex, Abdur Razzaque Sarker, Mark Sculpher, Beth Woods, Yue Xiao	2021	20
13	Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Value in Health ·Beth Woods, Neil Hawkins, W. Dunlop, Alison O'Toole, Steve Bramham-Jones	2012	19
14	Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S. Lung Cancer ·Gayathri Kumar, Beth Woods, Lisa M. Hess, Joseph Treat, Mark E. Boye, Peter Bryden, Katherine B. Winfree	2015	17
15	Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales Value in Health ·Rachel Allen, Peter Bryden, Kelly M. Grotzinger, Ceilidh Stapelkamp, Beth Woods	2016	15
16	Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma Lung Cancer ·Beth Woods, Noman Paracha, David A. Scott, Nicholas Thatcher	2011	14
17	Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin’s lymphoma in England and Wales Journal of Medical Economics ·Sarah Dewilde, Beth Woods, Jean‐Gabriel Castaigne, Christopher Parker, W. Dunlop	2013	14
18	Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis BMC Pulmonary Medicine ·David A. Scott, Beth Woods, Juliette C. Thompson, James F. Clark, Neil Hawkins, Mike Chambers, Bartolomé R. Celli, Peter M.A. Calverley	2015	14
19	Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems Health Economics ·Beth Woods, Aimée Fox, Mark Sculpher, Karl Claxton	2021	14
20	New paradigms for medical decision support and education: the Stanford Health Information Network for Education. PubMed ·Paul J. Godin, Robert A. Hubbs, Beth Woods, Min K. Tsai, D. Nag, T Rindfleish, Parvati Dev, Melmon Kl	1999	13

About Beth Woods

Beth Woods is a scholar working on Applied Microbiology and Biotechnology, Statistics, Probability and Uncertainty, Economics and Econometrics, Statistics and Probability and Genetics, having authored 59 papers that have together received 1.5k indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (19 papers), Meta-analysis and systematic reviews (9 papers), Antibiotic Use and Resistance (8 papers), Pharmaceutical Economics and Policy (8 papers), Global Maternal and Child Health (7 papers), Chronic Lymphocytic Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Statistical Methods in Clinical Trials (5 papers). The work is most often cited by research in Economics and Econometrics (370 citations), Statistics, Probability and Uncertainty (73 citations), Statistics and Probability (82 citations), Applied Microbiology and Biotechnology (20 citations) and Genetics (91 citations). Beth Woods has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include Mark Sculpher, Karl Claxton, Paul Revill, Neil Hawkins, David A. Scott, E.G. Sideris, Stephen Palmer, Marta Soares, Nicholas Latimer and Stuart Mealing. Their work appears in journals such as Value in Health, PharmacoEconomics, Health Technology Assessment, BMJ Global Health and BMC Medical Research Methodology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact